1. INVESTOR PRESENTATION
NEXT GENERATION
IMMUNOTHERAPIES
NEOVACS
APRIL 2016
INVESTOR PRESENTATION
Thérèse Croughs
Chief Medical Officer

2. Investor Presentation | April 2016
Disclaimer
This presentation and the information contained herein does not constitute or form part of, and should not be construed as, an offer or invitation to sell or subscribe for, or a solicitation of any offer or invitation to acquire, dispose of or subscribe for, securities of Neovacs S.A. (the “Company") in any country where such offer, invitation or subscription would be prohibited by law. The publication of this presentation in certain countries may violate applicable regulations. The new securities referred to herein have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the “Securities Act”) or any securities laws of any state within the US and may not be offered or sold, directly or indirectly, in or into the US, except pursuant to an available exemption from, or a transaction not subject to, the registration requirements of the Securities Act and in compliance with any applicable state securities laws of the US. Any offering of the Shares to be made in the US will be made only to a limited number of persons who: (i) are reasonably believed to be qualified institutional buyers (as defined in Rule 144A under the Securities Act) and/or institutional accredited investors (as defined in Regulation D under the Securities Act), and (ii) have executed and returned a securities issuance agreement to the Company. With respect to the member states of the European Economic Area which have implemented the Directive 2003/71/EC of the European Parliament and the Council of November 4, 2003, as amended in particular by Directive 2010/73/EC of the European Parliament and of the Council of November 24, 2010 (the “Prospectus Directive”), other than France, no action has been undertaken or will be undertaken to make an offer to the public of the securities referred to herein requiring a publication of a prospectus in any relevant member state. As a result, the securities may not and will not be offered in any relevant member state except in accordance with the exemptions set forth in Article 3(2) of the Prospectus Directive, if they have been implemented in that relevant member state, or under any other circumstances which do not require the publication by the Company of a prospectus pursuant to Article 3 of the Prospectus Directive and/or to applicable regulations of that relevant member state. In accordance with Article of the General Regulation of the Autorité des marchés financiers, no prospectus has been prepared nor will be disclosed by the Company or filed with the Autorité des marchés financiers in relation to the issuance of the new securities referred to herein. This presentation contains forward-looking statements. No guarantee can be given as to any of the events anticipated by the forward-looking statements, which are subject to inherent risks, including those described in the Document de Référence registered with the Autorité des marchés financiers under number R on December 11, 2014 and the Rapport Financier Annuel disclosed by the Company on April 2, 2015 (as updated upon the announcement of the issuance of the new securities referred to herein, as the case may be), changes in economic conditions, the financial markets or the markets in which the Company operates.
Investor Presentation | April 2016

3. University spin-off (Pierre and Marie Curie University) in 1993, Company formed in Seasoned leadership, 23-strong team (M.D., Pharm.D.,Ph.D.s), located in Paris and Boston
Active immunotherapy: using a patient’s own immune system to regulate inappropriate cytokine overproduction
Kinoids, new anti-cytokine therapeutic vaccines, IP protected until 2032
Corporate Highlights
3 products in auto-immune and inflammatory diseases, allergies and cancer:
2 phase II clinical studies in Lupus and Dermatomyositis (orphan disease)
2 pre-clinical products in 3 indications (Age-related Macular Degeneration, solid tumors, allergy)
A clinical-stage company developing immunotherapies
for auto-immune and chronic diseases
Inflammatory and autoimmune diseases, allergies and cancers: billion dollar markets
Company
Public Listing on Alternext Paris since April 2010 (ALNEV, ISIN: FR )
Approach
- Stellar Biotech (NASDAQ: SBOT) (TSX VENTURE: KLH) 
- CKD Pharmaceutical
Products
Pipeline
Markets
Financials
Partnership
Investor Presentation | April 2016

4. Kinoid Platform: Pipeline
Preclinical
Phase I
Phase II
Phase III
IFNα-Kinoid in SLE – Europe, Latin America, Asia, USA
VEGF-Kinoid in solid tumors
IFNα-Kinoid in Diabetes Type 1
Study design under evaluation
phI/II study results in 4Q2011
Phase IIb launched 10,2015
TNF-Kinoid
Most advanced program to launch in 2017
VEGF-Kinoid in AMD
Supportive data on IFN-K immunogenicity and down regulation on IFN-signature
IFNα-Kinoid in DM - EU
IL-4/IL-13 Kinoid in allergies
LARGE THERAPEUTIC OPPORTUNITIES WITH KINOID TECHNOLOGY
Investor Presentation | April 2016

5. Kinoid Technology: Vaccine-Like Approach to Treating Chronic Diseases
Conjugation and inactivation
Kinoid
Polyclonal antibodies to targeted cytokine
Targeted cytokine
Carrier protein
Components of active immunotherapy
Immunization
Stimulation of the body’s immune system
T cells generated by the carrier protein (KLH) bypass B cell tolerance to induce self polyclonal anti-cytokine antibodies:
Target multiple epitopes : Broad and sustained efficacy
Blocking of overproduced cytokine, and its pro inflammatory effects
Specific to cytokine: no cross-neutralization with other cytokines
No blocking anti-drug antibodies (ADA)
T cell tolerance towards the cytokine is NOT broken: no uncontrolled autoimmunity
Source: Bachmann et al, Nature Reviews 2005
Investor Presentation | April 2016

6. Investor Presentation | April 2016
The Kinoid Technology: Competitive Positioning vs. Monoclonal Antibodies
Natural polyclonal antibodies :
no risk of anti-drug antibody (ADA)
Binding to multiple epitopes vs. single epitopes
Lower cost of goods
More convenient
Sustained efficacy
Broader efficacy
5 injections i.m. the first year,
vs. once every 2 – 4 weeks i.v./s.c.,
without hospitalization
~ 1mg of protein/year
vs. > 1g /year with mAbs
KINOIDS: A MAJOR BREAKTHROUGH WITH THE POTENTIAL TO SUPERSEDE MONOCLONAL ANTIBODIES
Investor Presentation | April 2016

7. Biologic Penetration Limited by High Prices
Cost of treatment of selected biologics
Proportion of diagnosed patients receiving a biologic in 2010
/ yr
USA
France/Europe
Enbrel (Amgen/Pfizer) $ €
Humira (Abbvie) $ €
Remicade (J&J/Merck) $ €
Benlysta (GSK) $ €
Source: Corporate data, 2011 and Datamonitor Report on Benlysta
2014 sales of top 3 anti-TNF biologics
Drug (molecule)
Pharma
Sales (M$)
Growth
Humira (adalimumab)
ABBVIE
12,907
21%
Remicade (infliximab)
J&J / MERCK
9,907
11%
Enbrel (etanercept)
PFIZER/AMGEN
8,920 7%
Benlysta (GSK)
GSK
285
A MARKET WITH CONTINUED HIGH GROWTH POTENTIAL, ESPECIALLY FOR LESS COSTLY THERAPEUTICS, ESPECIALLY IN LUPUS
Note: (1) source: Datamonitor, August 2011
Investor Presentation | April 2016

8. Systemic Lupus Erythematosus (SLE) or Lupus
A chronic auto-immune disease
Auto-antibodies
Fluctuating disease course: relapses-remissions
Can affect all organs (skin, kidneys, liver, heart)
Accumulations of manifestations over time
Increased mortality
Population
Young women: Y, F:M ratio: 6-10:1
Blacks>Asians/Hispanics>Caucasians
No curative therapy
Largely undiagnosed
Prevalence
0.05% of the general population
By 2016, 470,000 patients suffering from SLE in the 7MM1 with an AGR of 0.8%2.
USA: up to 1.5 million (Lupus Foundation of America)
China : + 1 million3
Arthritis 84%
Serositis 36%
Nephritis 39%
CNS
inflammation
10%
Malar rash 58%
Photosensitivity 45%
Immune thrombocytopenia 5%
Source: adapted from Houssiau F 2008; (1) 7 Major Markets : US, Japan, France, Germany, Italy, UK, Spain; (2) GlobalData ; prevalent cases estimates for 2016 ; (3) company estimates
Investor Presentation | April 2016

9. IFNα-Kinoid And The Market For SLE
Significant market
US$ 3.5 billion estimate (2019)
18% CAGR potential by 2019
GSK $3.6 bn takeover of HGS (Benlysta)
An unmet medical need
Benlysta (GSK), first new drug in 50 years
FDA + EMA: “marginal efficacy”1
cost: 30,540 US$ per patient per year2
Market for lupus therapies 2010 vs. 2019
Million dollars
New data obtained by MedImmune supports Neovacs‘ approach with INFα-K vaccine
MedImmune presented: Phase II data (N=305) of its monoclonal antibody (MAb), anifrolumab, which targets the Type 1 INF receptor
Results(3) show :
compelling evidence that blocking Type 1 IFN system is efficient
Consistent clinical efficacy versus placebo in all disease scales
Greater efficacy in patients with a elevated IFN gene signature at baseline
Source: Datamonitor 2011
MARKET THAT HAS LITTLE COMPETITION AND SIZEABLE GROWTH PROSPECTS
Source: (1) FDA / (2) Datamonitor Report on Benlysta 2014, (3): Furie et al, Abstract 3223 ACR2015
Investor Presentation | April 2016

10. Kinoid Technology: Natural Polyclonal Approach
Current treatments
Neovacs treatment
Monoclonal antibodies
Injection of non-self Abs
Abs bind to one specific epitope of the cytokine
Risk of MAb rejection and loss of efficacy (Anti- drug Abs)
Polyclonal antibodies
Self Abs generated by the patient’s immune system
Abs bind to multiple epitopes of the targeted cytokine
Better and sustained antibody efficacy
Excellent tolerance
Monoclonal antibodies
Polyclonal antibodies
INDUCING A SAFE AND EFFECTIVE POLYCLONAL RESPONSE FROM THE BODY’S OWN IMMUNE SYSTEM
Investor Presentation | April 2016
Avril 2011 10

11. IFNα-Kinoid : Completed and Planned Clinical studies
2015
2016
2017
2018
IFNα-Kinoid program in SLE
IFNα-Kinoid Phase IIb in SLE: EU, Asia, LATAM
Objectives: biological efficacy and clinical response
N = 166; IFNα-Kinoid versus Placebo; Double-blind, Randomized
First patient in: 3Q2015 – Results mid-2017
IFNα-Kinoid program in Dermatomyositis (DM)
ODD EU-USA: Request 1Q-2017-, Designation 3Q-4Q-2017
Part 1. Phase II – Adults EU: first patient in: 2Q-2016, Results 4Q-2017, N = 30 pts
Part 2. Phase IIb/III – Adults EU-USA-Asia: first patient in 1Q-2018, Results 4Q-2019,
N = pts
Phase IIa/b – Pediatrics – EU-USA: first patient in 3Q-2017, Results 2Q-2019,
N = 9-18 pts
STRONG CLINICAL PORTFOLIO WITH IFNα-KINOID
Investor Presentation | April 2016

12. IFNα-Kinoid Phase I/II in SLE : study design and population
years
SLE ACR 4/11
SLEDAI 4-10
ANA and/or anti-dsDNA positive
Corticosteroid ≤ 20mg/day
No BILAG A
Double-blind, placebo controlled, 3:1
(IFN-K/Placebo)
28 pts, 7 countries, 12 centers
Staggered dose increase
Kinoid 30 mcg/dose vs placebo
Kinoid 60 mcg/dose vs placebo
Kinoid 120 mcg/dose vs placebo
Kinoid 240 mcg/dose vs placebo
Schedule of administration
3 IM injections, D0-D7-D28
4th dose at week 12 in 50% of patients
Objectives
Safety
Immune responses
Neutralization of IFN-alpha- and SLE- dysregulated genes
Investor Presentation | April 2016

13. 100% of SLE patients developed anti-IFN antibodies in IFN-K group
3 doses
Anti-IFNa antibody GMT
100
1000
10000
100000 50
150
200
250
300
350
30 mcg IFN-K
60 mcg IFN-K
120 mcg IFN-K
240 mcg IFN-K
Placebo
4 doses
Anti-KLH antibody GMT
NC50 (geometric mean)
Day
Increasing doses and number of injections of IFNα-Kinoid lead to increased anti-IFNα and anti-KLH Ab responses and neutralizing capacity response to IFNα
Source: Lauwerys et al, 2013, Arthritis & Rheum
Investor Presentation | April 2016

14. Polyclonal Antibody Response Neutralizes all IFNα subtypes
10 U/mL
Polyclonal antibodies
of an IFN-K immunized Patient (D964)
(Dilution)
9F3
Monoclonal Antibody anti-IFNα (concentration ng/mL)
A 2a
1/22475
<7.8 B2
1/8936 98 C
1/8857
>1000 D
1/9648 F
1/2493
329 G
1/10693 78 H2
1/9147 57 I
1/13354 J1
1/5270 K
1/16878 4b
1/10154 WA
1/10148
945
A 2b
1/22326
Neutralized
sub-types
13/13
+++
2/13: +++
5/13: +
Since most probably all IFNα subtypes are involved in SLE pathogenesis, these ex-vivo results demonstrate the strong neutralizing capacity of anti-IFNα Ab induced by IFN-K administration compared to MAb
IFNα
Neutralizing polyclonal anti-IFNα antibodies
Strong neutralization
Weak neutralization
No neutralization
9F3 : mAb deposited at ATCC by Genentech (in 2001 U.S. patent 7,087,726 B2)
Investor Presentation | April 2016

15. Investor Presentation | April 2016
Extended follow-up data from phase I/IIa trial confirms potent biological activity 4 years after end of trial
3 key results regarding anti-IFNα neutralizing generated by IFNα-Kinoid antibodies presented at Lupus 2015 congress in Vienna in September 20151:
Neutralizing Abs still present 4 years after the first immunization;
They continue to maintain normalization of IFNα signature;
Neutralizing Abs associated with the decreased expression of induced genes associated with B cell activation. B-cell activation, like the IFNα-signature, has been linked to the pathogenesis of SLE lupus2;
Neovacs has previously reported the strong level of biological activity of IFNα-Kinoid at 6 months after first immunization with IFNα-Kinoid3;
Further long term observation:
6 out of 6 patients still followed by Neovacs because they still have antibodies against IFNα, had no
Lupus flare since 4 years
Note: (1) J. Ducreux, et Al, IFNα-kinoid (IFN-K) induces neutralizing anti-IFNα antibodies that decrease the expression of IFN-induced and B cell activation associated transcripts : Analysis of extended follow-up data from the IFN-K Phase I/IIa study, Lupus 2015, Vienna 2015 Poster Session P04 Treatment. 2) Kiefer K, Oropallo MA, Cancro MP, et al. Immunol Cell Biol 2012; 90: ) Bernard Lauwerys et al., Arthritis & Rheumatism Vol. 65, No. 2, February 2013.
Investor Presentation | April 2016

16. Clinical Advisory Board - SLE
Pr. KIRYAKOS KIROU, MD, DSc, FACP
Mary Kirkland Center for Lupus Research, New-York
Director, Lupus Nephritis Program, Hospital for Special Surgery, New-York
Pr. ERIC HACHULLA, MD
Professor and clinical expert Centre Hospitalier Universitaire de Lille; Centre de Référence des Maladies Auto-immunes et Systémiques rares, France 
Pr. VIBEKE STRAND, MD, FACP, FACR
Clinical Professor, Adjunct, Division of Immunology and Rheumatology of the clinical faculty at Stanford University
Consultant in clinical research and regulatory affairs
Pr. FRÉDÉRIC HOUSSIAU, MD
Chief of Rheumatology Unit, SSS/IREC/RUMA, Cliniques Universitaires Saint Luc & Université Catholique de Louvain, Brussels, Belgium
Pr. JOAN MERRILL, MD
Professor of Medicine, Adjunct Professor, Oklahoma Medical Research Foundation; School of Pharmacy University of Oklahoma Health Sciences Center
Medical Director of the Lupus Foundation of America, and member of the Systemic Lupus International Collaborating Clinics
Pr. RONALD VAN VOLLENHOVEN, MD
Chief of the Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID) at the Karolinska Institute, and of the Clinical Trials Unit Rheumatology at the Karolinska University Hospital, Stockholm
Pr. BERNARD LAUWERYS, MD, PhD
Rheumatology Unit, SSS/IREC/RUMA, Cliniques Universitaires Saint Luc & Université Catholique de Louvain, Brussels, Belgium
Investor Presentation | April 2016

17. Investor Presentation | April 2016
IFNα-Kinoid & Phase 2b in SLE (IFN-K-002) Design & Clinical End-Points for Efficacy
Double-blind, randomized, placebo controlled
Population
Design
years
SLE ACR 4/11
SLEDAI ≥ 6
Moderate to severe
IFN gene signature positive
Corticosteroid ≤ 20mg/day
Double-blind, placebo controlled, 1:1
(IFN-K/Placebo)
166 pts, 19 countries, 100 centers
Dosing regimen
IFN-K 240 mcg/dose vs placebo D0-D7-D28
IFN-K 120 mcg/dose vs placebo M3-M6 (boost)
Objectives
Co-Primary end-points:
Biological Efficacy (decrease of IFN gene signature) and Clinical Efficacy ( using BICLA response)
Secondary end-points:
SRI-4 response
Mean N flares
Other clinical end points
Investor Presentation | April 2016

18. IFN-Kinoid Development Plan - SLE
2015
2016
2017
2018
2019
2020
2021 Q1 Q2 Q3 Q4
IMPD
Ph IIb - IFN-K-002 EU + Asia + LATAM + US
EXTENDED FOLLOW-UP (5 years)
IND
n = 178 evaluable pts
REGISTRY - South Korea
MAA SUBMISSION
South Korea (ODD)
Fast-Track US
PRIME -EMA
Registration strategy
ScAdvice (EMA)
FDA EOP2 meeting
Conditional MAA/BLA
4Q-2020
INTERIM RESULTS
250 pts - M12
IMPD
Full MAA/BLA SUBMISSION
3Q-2021
Ph III Study
Ph III Study
Preparation
Recruitment
Follow-Up/Procedure
Results
MAA/BLA filing
Investor Presentation | April 2016

19. IFN-K & Dermatomyositis
Autoimmune inflammatory disease characterized
by muscle weakness and skin rash, Unmet medical need:
Adult and juvenile DM
Orphan Disease in EU1 & US2:
Incidence: 1-10 new cases/million pop/year
Prevalence: 1/ – 1/50 000
Ratio F/M: 2/1, in USA, Black>Caucasian
Standard of care: CS and immunosuppressive drugs
Co-morbidities: notably cancer and side effects CS related
Diagnosis:
Muscle Biopsy: inflammatory cells in perivacular & perifascicular distribution + perifascicular atrophy
Skin: Gottrons papules and classic heliotrope rash
Lab parameters:
specific autoAb
IFN gene signature (type I) in blood & muscle biopsy
Heliotrope rash
Gottrons papules
Shawl sign
Inflammatory cells in perivacular
Elbow Rash
Gottrons papules
Notes: (1) 5/10 000; (2) <
Investor Presentation | April 2016

20. IFN-K & Dermatomyositis
Rationale to support a PoC in Humans
No single animal model fully reproduced human disease
IFN gene signature pathway documented (Baechler et al.2003, Greenberg et al, 2010, Allenbach et al, 2016, in press)
IFN-K induced neutralizing Ab in SLE patients (Lauwerys et al, 2013)
IFN-K decreased IFN gene signature in SLE patients (Lauwerys et al, 2013)
Safety data accumulated in Phase I/II study in SLE patients
Dosing regimen established in Phase I/II study in SLE patients
Population
Study Design:
years
Newly diagnosed or relapsing DM
Corticosteroid 1 mg/day or ≤ 70 mg/day
PoC study, Single-blind, placebo controlled, 1:1
(IFN-K/Placebo)
30 pts, 5 countries, 9 centers
Dosing regimen
IFN-K 240 mcg/dose vs placebo D0-D7-D28
IFN-K 120 mcg/dose vs placebo M3-M6 (boost)
Objectives
Primary end-points:
Production of anti-IFNα antibodies and Biological Efficacy (decrease of IFN gene signature)
Secondary end-points:
Safety, clinical efficacy (MMT8&5, accelerometer,…) IFN gene signature in muscle biopsy
Investor Presentation | April 2016

21. IFN-Kinoid Proposed Development Plan – DM
2014
2015
2016
2017
2018
2019
2020 Q1 Q2 Q3 Q4
IMPD
M M6 M12
IFN-K-DM-005 Ph II-Part 1 EU – n= 30 pts
EXTENDED FOLLOW-UP STUDY
Part 2 EU + US + Asia – n= pts
IND
MAA/BLA SUBMISSION
Fast-Track US
PRIME- Europe
ODD EU-US
IFN-K-DM-005?
CTA submission fin Dec – Approval March
FPI end March-beg April
PIP
Rare Ped Disease PRV US
Preparation
Recruitment
Follow-Up/Procedure
Results
Pediatrics Ph IIa/IIb – Part 1 - EU + US – n= 9-18 pts – 3 doses
Part 2 – EU + US – n= +15 pts
Investor Presentation | April 2016

22. EXPECTED RESULTS OF PHASE IIb TRIAL IN LUPUS
Major Events
IPO
Alternext Paris
€10 million Raised
2013
2014
2015
2017
2010
2011
2012
2016
FINAL RESULTS OF THE PHASE II STUDY IN CROHN’S
- The Kinoid has a very good safety and tolerability profile
- The ability of the Kinoid to induce an immune response is confirmed
Immunization against INFα shows positive effect on immune system in people with lupus
MIGUEL SIELER
named CEO
- Licensing agreement (IFNα-Kinoid in SLE and DM) for South Korea with CKD, Seoul
- €5 million
- Lupus, orphan disease in South Korea :
enabling to submit for registration without Phase III, directly after Phase IIb results early 2017,
aiming at a market entry early 2018
- Non-dilutive funding of €5 million, from Bpifrance
- To support industrial project to implement a production unit for the Kinoids in Paris region
FINAL RESULTS OF THE PHASE I/II STUDY IN LUPUS
NEOVACS ANNOUNCES TOP LINE PHASE IIB CLINICAL TRIAL RESULTS OF TNF-KINOID IN RA AND UPDATE ON CLINICAL PROGRAMS
EXPECTED RESULTS OF PHASE IIb TRIAL IN LUPUS
Mid-2017
- Agreement to establish a joint production company, Neostell SAS, in France on a 70/30% basis.
- To produce the Kinoids for Neovacs but also conjugated therapeutic vaccines for third parties
NEW INTERNATIONAL SCIENTIFIC COMMITTEE
IN NEW-YORK
Composed of leading world experts in immune therapy, chronical inflammatory and autoimmune diseases
Investor Presentation | April 2016

23. Shareholding structure and Stock information
Other historical investors
OTC AM
Alternext Paris
ISIN code: FR
1, 24 € (Closing April 6th, 2016)
Market cap: 39 M€
Average Vol.: 1000K shares / per day
Number of shares outstanding: 32,056,310
Founders
December 31, 2015
Novartis Venture Fund
Free Float
Besançon Participations
In €
Investor Presentation | April 2016

24. An experienced management team
MIGUEL SIELER Chief Executive Officer
32 years of an international career for Bayer. CEO of Bayer Korea up to 1994, then CEO of Bayer Pharma France until when he became Chairman and C.E.O of the Bayer Group in France until his retirement in 2008
Member of the board of Nexity S.A and Stratoz
Master of Law from the University of Tubingen, Germany and graduated from the Institut d’Etudes Politiques de Paris, France
THERESE CROUGHS Chief Medical Officer
Thérèse joined Neovacs in Previously she was Chief Medical Officer at Cytheris for over 6 years, a French biotech company acting in active immunotherapy, before as Director of BU Lauriad & NCE at BioAlliance Pharma following several years at Novo Nordisk as international medical adviser for EU clinical development of r-FVIIa in severe haemorrhages
She worked for 10 years at Bayer, as International Project Leader for rFVIII
Medical degree from the Catholic University of Louvain, Brussels, Belgium
BERNARD FANGET Vice President Pharmaceutical Development
Bernard joined Neovacs in 2005, he was previously Senior Vice President, Pharmaceutical Development, of Flamel Technologies and Prior to Flamel was Corporate Vice President, Global Industrialization, at Sanofi Pasteur
Degree in biological chemistry from the University of Lyon, France
GERALDINE GROUARD-VOGEL Chief Scientific Officer
Géraldine joined Neovacs in She previously worked at Sanofi-Pasteur USA in bacterial vaccine development and as a researcher at the Walter Reed Army Institute of Research at the Seattle University
Degree in Pharmacy from Angers University (France) and PhD in Immunology with Dr Jacques Banchereau at Schering-Plough Lyon (France)
She has authored several scientific publications in peer-reviewed journals
OLIVIER DHELLIN Director of Pharmaceutical Development
Olivier joined Neovacs in He previously held positions at Anosys (a US/French cell therapy biotech company), and research activities for 7 years at Gustave Roussy Institute (molecular biology and genomics) and Pasteur Institute where he was a post-doctorate fellow in molecular pharmacology. He had previously spent 4 years as a resident in several hospital departments (pediatrics, pharmacology and biochemistry)
Degree in Pharmacy (Paris XI University, France) and a PhD in Virology (Pierre et Marie Curie University, France)
NATHALIE THOMAS-PUJOL Head of Regulatory Affairs
Nathalie joins Neovacs in 2014 after more than 20 years in the pharmaceutical industry in regulatory affairs and clinical research, such as head of Regulatory Affairs EMEA at Cephalon/Teva. Previously, she worked for 15 years at Sanofi- Aventis R&D
Pharmacist Doctorate from the University of Rouen in France and a PhD in toxicology from the University of Paris VII in France
Investor Presentation | April 2016

25. Scientific Advisory Board
Pr. JACQUES BANCHEREAU, PhD
Président du SAB
Director of immunological sciences The Jackson Laboratory for Genomics Medicine, At the UConn Health Center
Baylor Institute for Immunology Research, Dallas, Texas, USA
Pr. BETTY DIAMOND, MD
Investigator & Head, Center for Autoimmune and Musculoskeletal Diseases, The Feinstein Institute for Medical Research
Professor of Molecular Medicine and Medicine, Hofstra North Shore-LIJ School of Medicine, Manhasset, NY
Pr. NAPOLEONE FERRARA, MD
Professor of Ophthalmology and Pathology Senior Deputy
Director for Basic Sciences, UC San Diego Health System - La Jolla, CA
Pr. MIRIAM MERAD, MD, PhD
Professor Oncological Sciences and Medicine, Tisch Cancer Institute, New York, USA
Director of the Human Immunomonitoring center, Tisch Cancer Institute, New York, USA
In 2013, Dr. Merad was the primary organizer of the prestigious Keystone conference on dendritic cell biology
Pr. BERNARD LAUWERYS, MD, PhD
Rheumatology Unit, SSS/IREC/RUMA, Cliniques Universitaires Saint Luc & Université Catholique de Louvain, Brussels, Belgium
Dr. VIRGINIA PASCUAL
Director, Center for Inflammation and Autoimmune Diseases
Director, Center for Personalized Medicine
Adjunct Professor of Pediatrics, University of Texas Southwestern Medical Center, Dallas, Texas
Adjunct Professor of Pediatrics, Mount Sinai School of Medicine, New York, USA
Adjunct Associate Professor of Biomedical Studies, Baylor University
Pr. LAURENCE ZITVOGEL, MD
Research Director at INSERM U1015, Gustave Roussy Cancer Campus
Center of Clinical Investigations in Biotherapies of Cancer (CICBT) 507, Villejuif, France
Investor Presentation | April 2016

26. Investor Presentation | April 2016
Thank you & Contact
Do not hesitate to contact us
Miguel Sieler CEO 3/5 impasse Reille Paris Tel:
Neovacs
Charlène Masson
Investor Relations &
Corporate Communication Manager
Tel:
NewCap Pierre Laurent / Valentine Brouchot
Investor Presentation | April 2016